XML 38 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Detail) (USD $)
 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended
Nov. 30, 2012
Oct. 31, 2012
Nov. 30, 2010
warrant
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Leases
Jun. 30, 2012
Mar. 29, 2007
Jun. 30, 2013
Stanley Medical Research Institute
Maximum
Feb. 28, 2011
Individual
Maximum
Jan. 31, 2013
Daiichi Sankyo Company Limited
Jun. 30, 2013
Daiichi Sankyo Company Limited
Scenario 1
Jan. 31, 2013
Daiichi Sankyo Company Limited
Maximum
Apr. 30, 2010
Helion Biotech ApS
Apr. 30, 2010
Helion Biotech ApS
Maximum
Jun. 30, 2013
Vulcan and Life Sciences Discovery Fund Authority
Oct. 31, 2010
Vulcan and Life Sciences Discovery Fund Authority
Oct. 31, 2010
Vulcan Incorporated
Oct. 31, 2010
Vulcan Incorporated
Warrant 1
Oct. 31, 2010
Vulcan Incorporated
Warrant 2
Oct. 31, 2010
Vulcan Incorporated
Warrant 3
Oct. 31, 2010
Life Sciences Discovery Fund Authority
Commitments and Contingencies Disclosure [Line Items]                                            
Potential future payments                 $ 12,800,000 $ 3,800,000   $ 23,500,000 $ 33,500,000   $ 6,900,000              
Research and development expense       9,564,000 7,558,000 16,691,000 14,804,000       50,000     500,000                
Potential future net proceeds                                 1,500,000,000          
Eligible expenses and expenditures deducted for computation of net proceeds                               25,000,000            
Number of warrants issued     3                                      
Warrants, exercisable, amount of shares               197,478                     133,333 133,333 133,333  
Warrants, term                                     5 years 5 years 5 years  
Warrants, exercise price per share               12.25                     20 30 40  
Amount payable under agreement                                   25,000,000        
Term of agreement                                   35 years        
Amount payable under agreement                                           25,000,000
Number of Options to extend the lease term           2                                
Options to extend the lease term, number of options           5 years                                
Remaining aggregate rent payable       61,700,000   61,700,000                                
Net lease incentives       4,400,000   4,400,000                                
Prior grants received, under review           1,100,000                                
Settlement agreement, one-time payment   3,940,000                                        
Defense costs paid by insurer associated with lawsuit           2,000,000                                
Litigation recovery 3,950,000                                          
Settlement agreement, related employment taxes incurred   $ 13,000